目的分析探讨小剂量利妥昔单抗治疗原发性免疫性血小板减少症的临床治疗效果。方法选择我院2011年2月～2015年1月之间收治的36例原发性免疫性血小板减少症患者作为观察对象，采用随机的方式将其分为观察组和对照组各18例。对照组患者给予标准剂量的 利妥昔单抗进行治疗；而观察组患者则采用小剂量利妥昔单抗治疗方法。分析对比两组患者的临床效果和治疗安全性。结果观察组患者的治疗有效率与对照组相比差异较小，无统计学意义（P ＞0.05）；而观察组患者在治疗之后的免疫球蛋白定量及淋巴细胞亚群与对照组之间的差异显著，且并发症发生率之间亦有显著差异，具有统计学意义（P＜0.05）。结论对原发性免疫性血小板减少症患者应用小剂量利妥昔单抗治疗的效果与标准剂量对照组无明显统计学差异。但是对免疫球蛋白的影响较小，安全性更高。%Objective To analyze the small dose of rituxan treatment the clinical therapeutic effect of primary immune thrombocytopenia. Methods Our hospital in February 2011 to January 2015 between the 36 cases of patients with primary immune thrombocytopenia as research object, USES the random, it can be divided into observation group and control group (n =18). Control group patients give standard doses of rituxan treatment; While the observation group of patients with small dose of rituxan treatment. Comparing the clinical effect of two groups of patients and treatment of security. Results Observation group of patients treatment efficient and differences are smaller than the control group, there is no statistical significance (P>0.05). And observation group of patients after treatment of immunoglobulin quantitative and lymphocyte significant difference between the group and the control group, and also has a significant difference between incidence of complications, with statistical significance (P<0.05). Conclusion In patients with primary immune thrombocytopenia application effect of small dose of rituxan treatment with standard dose control group no significant statistical differences. But have less effect on the immune globulin, higher security.
展开▼
